LABORATORY RESEARCH USE ONLY. NOT INTENDED FOR CONSUMPTION.

CJC-1295 + Ipamorelin — Published Research

Reviewed by: James S.| Last updated: April 29, 2026|For laboratory reference only

← Back to CJC-1295 + Ipamorelin product page

How to read this CJC-1295 + Ipamorelin research page

This page summarizes published literature for the component pathways commonly reviewed together in catalog contexts: modified GRF/GHRH analog signaling and Ipamorelin ghrelin-receptor signaling. It is structured for literature orientation and documentation review only.

  • Component framing: citations are grouped by receptor-system context rather than by protocol or intended use.
  • Research framing: summaries describe receptor assays and experimental models; they do not establish product claims or therapeutic outcomes.
  • Documentation links: compare the blend listing, COA hub, and research framework.

Panda Peptides products are for research use only. No dosing, administration, reconstitution, treatment, hormone-use, or human-use guidance is provided.

Research Library

Published research on these compounds — for educational purposes only

Dual receptor signaling

This combination has been studied in receptor-signaling models using coordinated peptide agonism. One component activates a class B GPCR pathway through cAMP/PKA signaling, while ipamorelin activates GHS-R1a through phospholipase C/IP3/calcium pathways. Co-stimulation of both receptor systems in pituitary models produced additive signaling output in published rat studies.

Bowers CY et al. “On the activity of a new synthetic hexapeptide in pituitary signaling models.” Endocrinology. 1984. PubMed

Ipamorelin Selectivity Profile

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a pentapeptide characterized by selective GHS-R1a activity in pituitary models. In swine pituitary cell culture models, ipamorelin stimulated GH release with an EC₅₀ of approximately 1.3 nM without significant effects on ACTH, cortisol, prolactin, or FSH/LH release at effective concentrations. This selectivity profile distinguishes it from earlier GHS compounds like GHRP-6 and hexarelin, which show broader hormonal stimulation.

Raun K et al. “Ipamorelin, a selective peptide agonist in pituitary models.” Eur J Endocrinol. 1998. PubMed

CJC-1295 (Mod GRF 1-29) Structure and Pharmacokinetics

CJC-1295 without DAC (also known as Modified GRF 1-29) is a tetra-substituted analog of GRF(1-29) with modifications at positions 2 (D-Ala), 8 (Gln), 15 (Ala), and 27 (Leu). These substitutions confer resistance to DPP-IV and other proteolytic enzymes, extending the biological half-life from the approximately 7-minute native peptide half-life to roughly 30 minutes. The peptide retains full agonist activity at the target receptor with equivalent binding affinity to native GRF(1-29).

Ionescu M, Frohman LA. “Pulsatile GH-axis signaling persists during continuous stimulation by CJC-1295, a long-acting GRF analog.” J Clin Endocrinol Metab. 2006. PubMed

Continue reviewing CJC-1295 + Ipamorelin

Use the research references above alongside Panda’s batch documentation and catalog specifications.

Disclaimer: All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use only. This page is provided for research-reference and documentation review only.

Reviewed by

James S.

Research content reviewer focused on peptide literature summaries, source quality, and reference clarity.

Editorial Review

Reviewed by Elizabeth D. and James S. — Panda Peptides Research Team.

Last reviewed: May 2026.

This content summarizes published laboratory literature for research-reference purposes only. Products referenced by Panda Peptides are sold strictly for controlled laboratory, analytical, or reference use and are not consumer products.